887 related articles for article (PubMed ID: 9402106)
1. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Lindner DJ; Borden EC
J Interferon Cytokine Res; 1997 Nov; 17(11):681-93. PubMed ID: 9402106
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
Lindner DJ; Borden EC; Kalvakolanu DV
Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis.
Lindner DJ; Borden EC
Int J Cancer; 1997 May; 71(3):456-61. PubMed ID: 9139884
[TBL] [Abstract][Full Text] [Related]
4. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Gibson DF; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC
Breast Cancer Res Treat; 1993; 25(2):141-50. PubMed ID: 8347846
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.
Lindner DJ; Kolla V; Kalvakolanu DV; Borden EC
Mol Cell Biochem; 1997 Feb; 167(1-2):169-77. PubMed ID: 9059994
[TBL] [Abstract][Full Text] [Related]
6. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen.
Abe-Hashimoto J; Kikuchi T; Matsumoto T; Nishii Y; Ogata E; Ikeda K
Cancer Res; 1993 Jun; 53(11):2534-7. PubMed ID: 8495416
[TBL] [Abstract][Full Text] [Related]
8. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
9. Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay.
Higashihara J; Saito T; Berens ME; Welander CE
Cancer Chemother Pharmacol; 1988; 22(3):215-22. PubMed ID: 3136942
[TBL] [Abstract][Full Text] [Related]
10. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
11. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
Reddel RR; Sutherland RL
Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human interferon-alpha 2a increases hormone receptor level of a human breast carcinoma xenograft in nude mice and enhances the anti-proliferative activity of tamoxifen.
Josui K; Kubota T; Kitajima M
Jpn J Cancer Res; 1992 Dec; 83(12):1347-53. PubMed ID: 1483948
[TBL] [Abstract][Full Text] [Related]
14. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
16. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer.
Tantivejkul K; Vucenik I; Eiseman J; Shamsuddin AM
Breast Cancer Res Treat; 2003 Jun; 79(3):301-12. PubMed ID: 12846414
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of colon and breast carcinoma cell growth by interleukin-4.
Toi M; Bicknell R; Harris AL
Cancer Res; 1992 Jan; 52(2):275-9. PubMed ID: 1728401
[TBL] [Abstract][Full Text] [Related]
18. Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.
Goldstein D; Bushmeyer SM; Witt PL; Jordan VC; Borden EC
Cancer Res; 1989 May; 49(10):2698-702. PubMed ID: 2469536
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.
Bauer JA; Morrison BH; Grane RW; Jacobs BS; Dabney S; Gamero AM; Carnevale KA; Smith DJ; Drazba J; Seetharam B; Lindner DJ
J Natl Cancer Inst; 2002 Jul; 94(13):1010-9. PubMed ID: 12096086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
